A Clinical Trial With KJ103 in Anti-GBM Disease

Subjects will administered KJ103 intravenously on D1 and adjunctively on D8

Hence treatment prevents formation of new anti-GBM antibodies.

Glucocorticoids inhibit the inflammation process.

PLEX removes the patient\'s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.